KPC PHARMACEUTICALS, INC. — Investor Relations & Filings
About KPC PHARMACEUTICALS, INC.
KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 昆药集团股份有限公司董事会战略与ESG委员会实施细则（2025年12月修订） | 2025-12-09 | Chinese | |
| 独立董事提名人声明与承诺（丁侃） | 2025-12-09 | Chinese | |
| 昆药集团股份有限公司董事、高级管理人员持有及买卖本公司股份的专项管理制度（2025年12月制定） | 2025-12-09 | Chinese | |
| 昆药集团股份有限公司内部审计管理制度（2025年12月修订） | 2025-12-09 | Chinese | |
| 昆药集团关于高级管理人员离任的公告 | 2025-12-09 | Chinese | |
| 昆药集团关于召开2025年第五次临时股东大会的通知 | 2025-12-09 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
15 filings
| |||||
| 40929779 | 昆药集团股份有限公司董事会战略与ESG委员会实施细则（2025年12月修订） | 2025-12-09 | Chinese | ||
| 40929776 | 独立董事提名人声明与承诺（丁侃） | 2025-12-09 | Chinese | ||
| 40929756 | 昆药集团股份有限公司董事、高级管理人员持有及买卖本公司股份的专项管理制度（2025年12月制定） | 2025-12-09 | Chinese | ||
| 40929746 | 昆药集团股份有限公司内部审计管理制度（2025年12月修订） | 2025-12-09 | Chinese | ||
| 40929737 | 昆药集团关于高级管理人员离任的公告 | 2025-12-09 | Chinese | ||
| 40929707 | 昆药集团关于召开2025年第五次临时股东大会的通知 | 2025-12-09 | Chinese | ||
| 40929697 | 独立董事候选人声明与承诺（丁侃） | 2025-12-09 | Chinese | ||
| 40929685 | 昆药集团股份有限公司董事会议事规则（2025年12月修订） | 2025-12-09 | Chinese | ||
| 40929673 | 昆药集团关于增补部分董事的公告 | 2025-12-09 | Chinese | ||
| 40929661 | 昆药集团股份有限公司董事会提名委员会实施细则（2025年12月修订） | 2025-12-09 | Chinese | ||
| 40929652 | 昆药集团十一届八次监事会决议公告 | 2025-12-09 | Chinese | ||
| 40929644 | 昆药集团股份有限公司董事会审计与风险控制委员会实施细则（2025年12月修订） | 2025-12-09 | Chinese | ||
| 40929624 | 昆药集团股份有限公司股东会议事规则（2025年12月修订） | 2025-12-09 | Chinese | ||
| 40929601 | 独立董事提名人声明与承诺（康彩练） | 2025-12-09 | Chinese | ||
| 40929594 | 昆药集团十一届十一次董事会决议公告 | 2025-12-09 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
KPC PHARMACEUTICALS, INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/56720/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=56720 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=56720 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=56720 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 56720}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for KPC PHARMACEUTICALS, INC. (id: 56720)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.